Jiangsu Nhwa Pharmaceutical Co., LTD engages in research, development, production, and sale of central nervous system products in China. The company offers APIs, solid preparation, water injection, and freeze-dried powder formulations for depression, anxiety disorders, insomnia, severe mental disorders, and neurodegenerative diseases. Its products include sufentanil citrate injection, oxaliplatin fumarate injection, alfentanil hydrochloride injection, oxycodone hydrochloride injection, olanzapine tablets, midazolam hydrochloride oral solution, clonazepam injection, lacosamide injection, micuronium injection, pregabalin capsules, vortioxetine hydrobromide tablets, tapentadone hydrochloride tablets, and oxycodone hydrochloride extended-release tablets. The company was founded in 1978 and is headquartered in Xuzhou, China.
Research context
Jiangsu Nhwa Pharmaceutical Co., LTD appears in PyInvesting’s Shenzhen Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Jiangsu Nhwa Pharmaceutical Co., LTD is currently in a long term downtrend where the price is trading 4.3% below its 200 day moving average.
From a valuation standpoint, the stock is 53.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.5.
Jiangsu Nhwa Pharmaceutical Co., LTD's total revenue rose by 3.7% to $987M since the same quarter in the previous year.
Its net income has increased by 10.4% to $157M since the same quarter in the previous year.
Finally, its free cash flow grew by 278.5% to $532M since the same quarter in the previous year.
Based on the above factors, Jiangsu Nhwa Pharmaceutical Co., LTD gets an overall score of 4/5.